ATE354369T1 - Verwendung von galectin-2 - Google Patents

Verwendung von galectin-2

Info

Publication number
ATE354369T1
ATE354369T1 AT04007345T AT04007345T ATE354369T1 AT E354369 T1 ATE354369 T1 AT E354369T1 AT 04007345 T AT04007345 T AT 04007345T AT 04007345 T AT04007345 T AT 04007345T AT E354369 T1 ATE354369 T1 AT E354369T1
Authority
AT
Austria
Prior art keywords
galectin
nucleic acid
complementary strand
coding
cells
Prior art date
Application number
AT04007345T
Other languages
English (en)
Inventor
Axel Dignass
Stefan Rosewicz
Andreas Sturm
Original Assignee
Charite Universitaetsmedizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin filed Critical Charite Universitaetsmedizin
Application granted granted Critical
Publication of ATE354369T1 publication Critical patent/ATE354369T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
AT04007345T 2004-03-26 2004-03-26 Verwendung von galectin-2 ATE354369T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04007345A EP1593386B1 (de) 2004-03-26 2004-03-26 Verwendung von Galectin-2

Publications (1)

Publication Number Publication Date
ATE354369T1 true ATE354369T1 (de) 2007-03-15

Family

ID=34924535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04007345T ATE354369T1 (de) 2004-03-26 2004-03-26 Verwendung von galectin-2

Country Status (4)

Country Link
EP (1) EP1593386B1 (de)
AT (1) ATE354369T1 (de)
DE (1) DE602004004875T2 (de)
ES (1) ES2282750T3 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908476A1 (de) * 2006-09-28 2008-04-09 Charite-Universitätsmedizin Berlin Galectin-2 zur Behandlung von Hautentzündungskrankheiten
US20110129485A1 (en) * 2008-05-19 2011-06-02 The University Of Queensland Modified Galectin-2 and Uses Thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002322082A (ja) * 2001-04-26 2002-11-08 Purotejiin:Kk 腎炎の予防・治療剤
US20040023855A1 (en) * 2002-04-08 2004-02-05 John Constance M. Biologic modulations with nanoparticles

Also Published As

Publication number Publication date
DE602004004875T2 (de) 2007-10-31
DE602004004875D1 (de) 2007-04-05
EP1593386A1 (de) 2005-11-09
EP1593386B1 (de) 2007-02-21
ES2282750T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
BR0211079A (pt) Processos para a modificação genética de células hematopoiéticas progenitoras e empregos das células modificadas
DK1696904T3 (da) Anvendelse af rotigotin til behandling eller forebyggelse af dopaminergt neurontab
CY1117312T1 (el) Θεραπευτικη αγωγη συνουκλεϊνοπαθειων
DE502004007735D1 (en) Flächiges implantat
ES2173812B1 (es) Dermis artificial y metodo de obtencion.
PT1613589E (pt) Nova difenilazetidinona com características fisiológicas melhoradas, processo para a sua preparação, medicamentos contendo este composto e sua utilização
WO2008071438A3 (en) Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor
WO2008100376A3 (en) Truncation variants of sirt1 and methods of use thereof
PL1699480T3 (pl) Allogeniczny przeciwnowotworowy czynnik terapeutyczny
MX2009010451A (es) Peptidos con capacidad para unirse a la interleuquina 10 (il-10).
DE502004008793D1 (de)
DE50302220D1 (de) Verwendung von Rhodium-vernetzenden Siliconelastomeren für die Herstellung von Backformen
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
PL1753512T3 (pl) Tetrahydropirydotiofeny
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
ATE354369T1 (de) Verwendung von galectin-2
NO20070780L (no) Celloverflateprotein.
EA200970970A1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидо-4-пиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения моторных нарушений, связанных с болезнью паркинсона
DE60331934D1 (de) Mutierter androgenrezeptor, diesen exprimierende krebszellen, verfahren zur konstruktion davon und verwendung davon
DE602004016664D1 (de) Autologous selbst-toleranz induzierende zellen monozytären ursprungs und ihren verwendung in artzneimitteln
DE602005005145D1 (de) Medizinische Elektrodenanordnung mit Möglichkeit zur Überwachung der Behandlung
WO2006113220A3 (en) Transgenic mammals expressing human preproinsulin
ITBO20020678A0 (it) Manipolo dentale per la rimozione del tartaro.
IL189597A0 (en) Methods of using il-21
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties